Tue, Sep 23, 2014, 10:48 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.


  • hospitalave hospitalave May 9, 2011 2:09 PM Flag

    Immune Response BioPharma David Buswell

    From what I understand David Buswell and the folks at Immune Response BioPharma are claiming that the research from Orchestra Therapeutics/Immune Response was abandoned and the law allows them to now claim it without offering any compensation to the investors who still hold stock in OCHT/IMNR. During the last two years that Immune Response/Orchestra Thera was operating Kevin Kimberlin was obtaining all the intellectual property rights to the research in return for operating money he was giving them through Spencer Trask. Its hard to imagine that he abandoned research he purchased (I know that as a stock holder and investor I certainly didn't abandon any of the research). My guess is that Kevin Kimberlin and Spencer Trask are behind Immune Response BioPharma and they have basically maneuvered the intellectual property rights so that they could gain sole ownership and start a new company while leaving the investors of IMNR/OCHT behind with nothing.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It sounds like Buswell's dad passed from sepsis & got involved to develop a drug in that area he calls Sepsicillin reading the PR on the sepsis drug, from the website and makes it clear that is the company focus and direction and it looks like he has no prior connection with the IRC/Orchestra. I doubt he knows kk or any of the financial backers.. but he sure has revamped this company quickly i have not never seen anything like it before. To keep knocking him and all this talk of doing something wrong don't hold water it bk'd on its own no fault of Buswell i don't recall him being in management.

      XOMA had a sepsis drug in BPI but failed i wonder if this new company is using the same antibody Rbpi21??? Neuprex went through lots ups and downs bio investing is not always a sure thing, XOMA we had highs and lows and our stock has been in the penny range. If Buswell can make IRC a winner more power to him. I notice some big names on their board including the inventor of NeuroVax.

      This might be a the next Amgen if they get it right. I agree the bk was handled poorly but mistakes happen the MS drug looks pretty darn good. XOMA has many things in common but did not bk to get a blockbuster drug approved takes time money and a little luck. The mouse antibody technology was not ready 10-20 years ago much like the AIDS technology the FDA and medical community did not want to risk these new types of drugs but today these are common drugs getting approved. Buswell is doing a world of good for sick patients i would get off rag and get on the bandwagon this might be a winner yet.

      XOMA is still kicking why shouldn't IRC be too, put that in your pipe and smoke it i like Buswell he has fight in him.

    • How can i get shares in the new company?

    • I guess only time will tell. I do remain grateful that Mr. Buswell is making an effort to revive interest in the science. Ideally, he'll succeeed where many others have failed.

    • Ideally, you will contact kk or a representative of Spencer Trask and supply the readers of this board with an answer regarding the ownership of certain science.

0.0050.000(0.00%)May 4 9:30 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.